Phase 3 Readout
ENTA: Phase 3 Topline: A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older
June 1, 2026 · chemo-immunotherapy. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 1, 2026
- Company
- ENANTA PHARMACEUTICALS INC (ENTA)
- Drug
- chemo-immunotherapy
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older
- Drug
- chemo-immunotherapy
- Indication
- Advanced Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8